Compare BioNTech SE - ADR (BNTX) vs Endeavour Silver Corp (EXK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Endeavour Silver Corp — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while Endeavour Silver Corp trades at $10.59 (market cap $3.14B). The key difference: BioNTech SE - ADR is far larger — about 7.4× Endeavour Silver Corp's market cap, and Endeavour Silver Corp is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | EXK | |
|---|---|---|
Market Cap | $23.31B | $3.14B |
Sector | Health | Basic Materials |
52-Week High | $119.34 | $14.12 |
52-Week Low | $83.89 | $5.31 |
Enterprise Value | $6.60B | $3.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
EXK trades at $10.61, up 3.61% today, with a bullish technical signal from moving averages and a consensus analyst price target of $15.50. Recent Q2 2026 earnings matched estimates at $0.15 per share, while Q1 2026 beat expectations. The company reported strong production growth and secured a $25 million credit facility in August 2026, supporting operational expansion.
Outlook is positive due to rising revenue, improved profitability projected for 2026, and favorable metal prices. Risks include high P/E ratio of 52.95, volatile earnings history, and dependence on commodity markets. Institutional sentiment is bullish with 78.57% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →
